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Assessment of human plasma and urine sample
preparation for reproducible and high-throughput
UHPLC-MS clinical metabolic phenotyping†
Andrew D. Southam, *a,b Liam D. Haglington, a Lukáš Najdekr, a,b
Andris Jankevics, a,b Ralf J. M. Weber a,b and Warwick B. Dunn a,b,c
Clinical metabolic phenotyping employs metabolomics and lipidomics to detect and measure hundreds
to thousands of metabolites and lipids within human samples. This approach aims to identify metabolite
and lipid changes between phenotypes (e.g. disease status) that aid understanding of biochemical mecha-
nisms driving the phenotype. Sample preparation is a critical step in clinical metabolic phenotyping: it
must be reproducible and give a high extraction yield of metabolites and lipids, and in high-throughput
studies it needs to be rapid. Here, we assessed the extraction of polar metabolites from human urine and
polar metabolites and lipids from human plasma for analysis by ultra-high-performance liquid chromato-
graphy-mass spectrometry (UHPLC-MS) metabolomics and lipidomics. We evaluated several monophasic
(urine and plasma) and biphasic (plasma) extractions, and we also tested alterations to (a) solvent–biofluid
incubation time and temperature during monophasic extraction, and (b) phase partitioning time during
biphasic extraction. Extracts were analysed by three UHPLC-MS assays: (i) hydrophilic interaction chrom-
atography (HILIC) for urine and plasma, (ii) C18 aqueous reversed phase for urine, and (iii) C18 reversed
phase for plasma lipids, and the yield and reproducibility of each method was assessed. We measured
UHPLC-MS injection reproducibility as well as sample preparation reproducibility to assess sample solvent
composition compatibility with UHPLC-MS and to pinpoint the origin of variance within the methods. For
HILIC UHPLC-MS plasma and urine analysis, monophasic 50 : 50 methanol : acetonitrile had the most
detected putatively-identified polar metabolites with high method reproducibility. This method had the
highest lipid yield for plasma extracts analysed by the HILIC method. If lipid removal from the plasma
polar HILIC extract is required, then the biphasic methanol/chloroform/water method is recommended.
For C18 (aqueous) UHPLC-MS urine analysis, 50 : 50 methanol : water had high reproducibility and yield.
For C18 UHPLC-MS plasma lipidomics, monophasic 100% isopropanol had the highest detection response
of all annotated lipid classes with high reproducibility. Increasing monophasic incubation time and temp-
erature had little benefit on metabolite and lipid yield and reproducibility for all methods.
1. Introduction
Clinical metabolic phenotyping measures the relative amounts
of a wide range of detectable small molecules (metabolites and
lipids) in clinical samples (including plasma, serum, urine,
primary and immortalised cells, tissue, cerebrospinal fluid,
saliva and faeces1,2). This is commonly fulfilled by ultra-high
performance liquid chromatography-mass spectrometry
(UHPLC-MS),3 gas chromatography-mass spectrometry,4 direct
infusion-mass spectrometry5 or nuclear magnetic resonance
spectroscopy.6 Metabolic phenotyping can be rapid, high-
throughput and a low-cost analysis1 (though not always
applied with these goals), and is low- or non-invasive to
patients when utilising samples such as plasma, serum or
urine. The metabolome or lipidome (total metabolite or lipid
measurement from samples) is a metabolic phenotype that
defines interactions between genotype (or genotypes when
considering human and gut microbe genomes), environment
and lifestyle at a metabolic level.1,2 Levels of metabolites and
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lipids can be compared across phenotypes providing a power-
ful tool to rapidly understand and monitor many aspects of
human health and disease including: disease biomarker
identification and understanding disease mechanisms;7
patient stratification for disease classification or therapy (pre-
cision medicine);8 understanding drug toxicology;9 and under-
standing the benefits of exercise, nutrition and microbiome
interaction.10,11
Sample preparation is a critical step in metabolomics and
lipidomics. It needs to be reproducible, sensitive (to maximise
metabolite and lipid extraction recovery) and should efficiently
and rapidly denature proteins to halt residual enzymatic
activity.12–14 Methods which are high-throughput and lend
themselves to automation provide opportunities to increase
sample-throughput and the size of studies. Here we assess and
subsequently recommend appropriate protocols of plasma (and
serum by its association) and urine preparation for analysis by
UHPLC-MS metabolomics (both sample types) and lipidomics
(plasma only). Plasma (or serum) is a whole organism extra-
cellular matrix containing cumulative levels of metabolites and
lipids: (a) from bodily ingestion or excretion and (b) taken up
and excreted by organs and cells within the body. Plasma or
serum preparation methods should remove other biochemicals
(proteins, RNA and DNA) and extract metabolites and lipids
into a liquid solvent suitable for analysis. Such approaches can
be: (i) monophasic – the addition of a water-miscible organic
solvent to extract soluble compounds into a single phase;15 and
(ii) biphasic – the addition of immiscible organic solvent(s)
and water (water provided by the biofluid and/or added water)
to simultaneously extract hydrophilic metabolites and lipophi-
lic metabolites into two separate phases.13 Monophasic extracts
can be immediately analysed (post-centrifugation) if the extrac-
tion solvents are compatible with UHPLC-MS.12,15 For biphasic
extractions13 (and monophasic extractions using non-
UHPLC-MS-compatible solvents16) samples are dried and
reconstituted in an appropriate solvent before analysis, thus
increasing sample preparation complexity and time. The extrac-
tion solvent(s) influences metabolite/lipid solubility and
protein removal efficiency12,15 (sample stability is decreased if
enzyme activity is not fully inactivated14).
For monophasic polar metabolite extraction from serum or
plasma, methanol is highly regarded, giving good metabolite
extraction yield, efficient deprotenisation and high
reproducibility.15,17,18 Ethanol : methanol (1 : 1) has shown
positive results,18 but decreasing solvent polarity would limit
highly polar compound recovery. Acetonitrile divides opinion:
it has been shown as both good19 and bad17,20 in terms of
reproducibility, extraction efficiency and protein denaturation.
Monophasic serum or plasma lipid extraction solvents compa-
tible with direct UHPLC-MS analysis include isopropanol,
1-butanol : methanol mix, methanol, ethanol and
acetonitrile.12,20,21 Monophasic lipid extraction solvents that
require drying and reconstitution before analysis include
methanol : chloroform21,22 and methanol : methyl tert-butyl
ether (MTBE) : chloroform.16,22 Isopropanol is highly regarded
for lipid recovery and method simplicity.12
Biphasic plasma and serum extractions simultaneously
extract polar compounds and lipids into two separate phases.
This is beneficial (i) where insufficient sample volume exists
for two separate extractions, (ii) to remove salts and polar com-
pounds from the lipid extract,23 and (iii) to remove glyceropho-
spholipids from the polar extract which can cause matrix
effects. The latter two points [(ii) and (iii)] reduce UHPLC-MS
ionisation suppression24 and MS source fouling, which poten-
tially can increase detection sensitivity. Biphasic extractions
are longer protocols with more steps than monophasic prep-
arations and often (but not always) extracts need drying and
reconstitution before UHPLC-MS analysis. This reduces extrac-
tion speed and potentially increases technical variance.
Chloroform/methanol/water,12,13,16,22 dichloromethane/metha-
nol/water,12 dichloromethane/methanol/saline25 and MTBE/
methanol/water12,13,16 have been applied. Dichloromethane/
methanol/saline was comparable to chloroform/methanol/
saline for serum lipid extraction efficiency,25 while MTBE/
methanol/water plasma extraction using an optimised ratio of
2.6 : 2.0 : 2.4 was more reproducible than chloroform/metha-
nol/water (for lipid extracts) and had a higher polar metabolite
yield.13 Biphasic serum and plasma extractions generally have
lower polar metabolite26 and lipid12,16,22 yields compared to
monophasic extractions.
Urine is a whole organism excretion matrix, which informs
on whole body changes including gut microbial metabolism.
Urine from patients with healthy kidneys contain very little
protein, therefore the use of protein-denaturing organic sol-
vents is not essential.27 Preparation protocols include: (i) urine
dilution with water and centrifugation prior to UHPLC-MS ana-
lysis28 (using sodium azide28 or the sample filtering29 to
prevent microorganism growth); and (ii) the addition of
organic solvents including methanol or acetonitrile.30,31
Organic solvent use is beneficial for clinical metabolic pheno-
typing as it rapidly eliminates microorganisms and removes
any residual protein from samples, which is important if
patients have renal damage induced proteinuria – a side effect
of some diseases (e.g. multiple myeloma32) and clinical treat-
ments (e.g. chemotherapy33).
An important consideration for monophasic extraction
methods is the time and temperature used during the incu-
bation of biofluids with solvent to achieve the most efficient
metabolite and lipid extraction. However, the limited available
evidence suggests these factors are likely not important, e.g.
varying time (10 or 120 min) and temperature (ice or −20 °C)
during the monophasic extraction of plasma with methanol
had little effect on peak areas.17 For biphasic extractions of
tissue samples, increasing phase separation time can increase
compounds reproducibility and yield.14
Several biofluid preparation studies exist; however, studies
often have different conclusions which are sometimes
conflicting.17,19 Published work rarely investigates lipids
extracted by polar preparation methods (with few lipid species
covered in the studies that exist34). Previous studies do not
indicate the proportion of variance arising from (a) the sample
preparation and (b) the detection method, which is key to
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understand where in the whole process improvements could
be made to improve the methods. Such analysis would also
allow an understanding of the compatibility of different
sample solvent composition with UHPLC-MS methods. Few
studies test changes in variance and yield in relation to key
incubation preparation steps: we were only able to find a
single study that tests changes to solvent–biofluid incubation17
and none that test the influence of phase partition incubation
on yield and reproducibility for biofluid biphasic methods. In
this current study we provide greater clarity on the above
points. Here, we characterise several different solvents for the
monophasic and biphasic extraction of polar metabolites and
lipids from plasma, and the monophasic extraction of polar
metabolites from urine. We test the influence of (i) monopha-
sic solvent–biofluid incubation time and temperature and (ii)
biphasic partition time. Methods were compared in terms of
reproducibility (peak area relative standard deviation) and
compound recovery (number and response of detected identi-
fied compounds – putative and MS/MS annotated). A key aim
was to test methods that avoid sample drying and re-consti-
tution (monophasic preparations where samples are directly
analysed by UHPLC-MS after preparation). Thus, we also test
solvent suitability for UHPLC-MS by assessing injection repli-
cates. For polar sample preparations we also investigate the




Human urine and plasma (Seralab, BioIVT; received frozen)
were split into 50 μL aliquots and frozen at −80 °C until prepa-
ration. Acetonitrile (ACN), methanol (MeOH), water (H2O), and
isopropanol (propan-2-ol, IPA) were all LC-MS grade (Optima
brand, Fisher Scientific). Chloroform (CHCl3), dichloro-
methane (DCM), and methyl tert-butyl ether (MTBE) were all
HPLC grade (Fisher Scientific).
2.2. Experimental design
For each tested sample preparation condition: (i) n = 3 sample
preparation replicates were analysed, and (ii) n = 3 UHPLC-MS
injection replicates were analysed (a single preparation re-
injected 3 times). Data was assessed: (i) across sample prepa-
ration replicates to define sample preparation variance and
yield, and (ii) across UHPLC-MS injection replicates to define
UHPLC-MS variance and yield.
2.3. Urine monophasic sample preparation
50 μL urine (thawed on ice) and 150 μL of ice-cold solvent
(100% ACN or 100% MeOH or 50 : 50 ACN : H2O or 50 : 50
MeOH : H2O or 50 : 50 ACN :MeOH) were mixed, vortexed (120
s) and then: (i) not incubated, (ii) incubated at 4 °C for 60 min
or (iii) incubated at −20 °C for 60 min. Samples were centri-
fuged (21 000g, 20 min, 4 °C) and 100 μL of the supernatant
was aliquoted into a low recovery volume HPLC vial
(Chromatography Direct, UK). n = 4 extraction replicates were
conducted for each solvent type and preparation condition (n =
3 of these were analysed; and the remaining n = 1 was used to
create a pooled QC sample, see ‘Extract blank and quality
control (QC) sample preparation’ section).
2.4. Plasma monophasic sample preparation
This protocol was the same as the urine monophasic prepa-
ration except 50 μL plasma was used instead of urine and
different solvents were used: (a) for polar metabolite extraction
and subsequent HILIC UHPLC-MS analysis the added solvent
was 100% ACN or 100% MeOH or 50 : 50 ACN :MeOH; and (b)
for lipid extraction and subsequent C18 reversed-phase lipid
UHPLC-MS analysis the added solvent was 100% ACN or
25 : 75 ACN : IPA or 50 : 50 ACN : IPA or 75 : 25 ACN : IPA or
100% IPA. In all cases the biofluid : solvent ratio was 1 : 3.
2.5. Plasma biphasic sample preparation
Three biphasic extractions were applied (a)
CHCl3 : MeOH : H2O, (b) DCM :MeOH : H2O or (c)
MTBE : MeOH : H2O, as described previously.
13,14,23 For the
CHCl3 : MeOH : H2O method, 320 μL ice-cold methanol and
78 μL ice-cold water was added to plasma (50 μL, thawed on
ice) and vortexted (60 s). Then, 320 μL ice-cold chloroform and
160 μL ice-cold water was added and sample was vortexed (60
s), incubated (on ice, 10 min) and centrifuged (21 000g,
10 min, 4 °C). The final solvent ratio was 2 : 2 : 1.8
CHCl3 : MeOH : H2O (assuming plasma is 100% water). The
final biofluid : solvent ratio was 1 : 17.6 for this method. The
sample was set at room temperature (approximately 20 °C) to
allow biphase partitioning for either: (i) 1 min or (ii) 20 min
70% of the polar phase (377 μL) was removed and dried in a
SpeedVac sample concentrator (Savant SPD111V230, Thermo
Fisher Scientific). 70% of the non-polar phase (273 μL) was
removed and dried using a nitrogen blow down drier (Techne
FSC400D, Thermo Fisher Scientific). The DCM :MeOH : H2O
method was conducted as above except: dichloromethane was
used instead of chloroform; here 70% of the final polar phase
was 442 μL and 70% of the non-polar phase was 228 μL. The
final biofluid : solvent ratio was 1 : 17.6 for this method. The
MTBE : MeOH : H2O method used different solvent ratios to
the two methods above (final solvent ratio of
2.6 : 2 : 2.4 MTBE :MeOH : H2O; final biofluid : solvent ratio
was 1 : 21.4).13 This was conducted as for the
CHCl3 : MeOH : H2O method above except: initially 320 μL ice-
cold methanol and 78 μL ice-cold water was added to the
plasma (50 μL); and the second solvent addition step was
416 μL ice-cold MTBE and 256 μL ice-cold water. Here, 70% of
the final polar phase was 549 μL and 70% of the non-polar
phase was 235 μL. All polar extracts were resuspended in
140 μL 75 : 25 ACN : H2O and non-polar extracts were resus-
pended in 140 μL 75 : 25 IPA : H2O, to match the plasma
dilution of the monophasic methods (and the same solvent
composition as the 100% ACN or 100% IPA monophasic prep-
arations, above). Samples were vortexed (30 s), centrifuged
(21 000g, 20 min, 4 °C) and 100 μL of the supernatant was ali-
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quoted into a low recovery volume HPLC vial. n = 4 extraction
replicates were done for each solvent type and extraction con-
dition (n = 3 of these were analysed; and the remaining n = 1
was used to create a pooled QC sample, see ‘Extract blank and
quality control (QC) sample preparation’ section).
2.6. Extract blank and quality control (QC) sample
preparation
Extract blank samples were prepared for each method by sub-
stituting 50 μL of water for the plasma or urine. A pooled QC
sample was created for each UHPLC-MS assay by pooling the
4th extraction replicate prior to the final centrifugation step for
each method. The QC pool was vortexed (60 s), centrifuged
(21 000g, 10 min, 4 °C) and 100 μL of the supernatant was ali-
quoted into low recovery volume HPLC vials.
2.7. Ultra-high performance liquid chromatography-mass
spectrometry (UHPLC-MS)
The samples (maintained at 4 °C) were analysed by applying
three Ultra Performance Liquid Chromatography-Mass
Spectrometry (UHPLC-MS) methods using a Dionex UltiMate
3000 Rapid Separation UHPLC system (Thermo Fisher
Scientific, MA, USA) coupled with a heated electrospray Q
Exactive Focus mass spectrometer (Thermo Fisher Scientific,
MA, USA). Three separate UHPLC-MS assays were applied
(assay 1, assay 2, and assay 3). Urine preparations were ana-
lysed by assays 1 and 2. Polar plasma preparations were ana-
lysed by assay 1. Lipid (non-polar) plasma preparations were
analysed by assay 3.
Assay 1 was a HILIC method using an Accucore-150-Amide-
HILIC column (100 × 2.1 mm, 2.6 μm, Thermo Fisher
Scientific, MA, USA) as used previously.35 Mobile phase A: 95%
acetonitrile/water (10 mM ammonium formate, 0.1% formic
acid); mobile phase B: 50% acetonitrile/water (10 mM
ammonium formate, 0.1% formic acid). Gradient: t = 0.0, 1%
B; t = 1.0, 1% B; t = 3.0, 15% B; t = 6.0, 50% B; t = 9.0, 95% B; t
= 10.0, 95% B; t = 10.5, 1% B; t = 14.0, 1% B. All changes were
linear (curve = 5) and the flow rate was 0.50 mL min−1.
Column temperature was 35 °C and injection volume was 2 μL.
Data were acquired in positive and negative ionisation modes
separately (70–1050 m/z) with a resolution of 70 000 (FWHM at
m/z 200). Ion source parameters: sheath gas = 53 arbitrary
units, aux. gas = 14 arbitrary units, sweep gas = 3 arbitrary
units, spray voltage = 3.5 kV (positive ion)/2.7 kV (negative
ion), capillary temp. = 269 °C (positive ion)/320 °C (negative
ion), aux. gas heater temp. = 438 °C (positive ion)/320 °C
(negative ion). Data dependent MS2 in ‘Discovery mode’ was
applied to three QC samples over three mass ranges (70–200
m/z; 200–400 m/z; 400–1000 m/z) using following settings:
resolution = 17 500; isolation width = 3.0 m/z; stepped normal-
ised collision energies = 25, 60, 100%.
Assay 2 was an aqueous reversed phase method using a
Hypersil GOLD C18 (aq.) column (100 × 2.1 mm, 1.9 µm;
Thermo Fisher Scientific, MA, USA). Mobile phase A: water
(0.1% formic acid); mobile phase B: acetonitrile (0.1% formic
acid). Gradient: t = 0.0, 1% B; t = 0.5, 1% B; t = 2.0, 50% B; t =
9.0, 99% B; t = 10.0, 99% B; t = 10.5, 1% B; t = 15.0, 1% B. All
changes were linear (curve = 5) and the flow rate was 0.30 mL
min−1. Column temperature was 45 °C and injection volume
was 2 μL. Data were acquired in positive and negative ionis-
ation modes separately (100–1500 m/z) with a resolution of
70 000. Ion source parameters: sheath gas = 48 arbitrary units,
aux. gas = 11 arbitrary units, sweep gas = 2 arbitrary units,
spray voltage = 3.5 kV (positive ion)/2.5 kV (negative ion), capil-
lary temp. = 256 °C, aux. gas heater temp. = 413 °C. Data
dependent MS2 in ‘Discovery mode’ was applied to three QC
samples over three mass ranges (100–300 m/z; 300–600 m/z;
600–1500 m/z) using following settings: resolution = 17 500;
isolation width = 3.0 m/z; stepped normalised collision ener-
gies = 20, 50, 80%.
Assay 3 was a reversed phase lipid analysis method using a
Hypersil GOLD C18 column (100 × 2.1 mm, 1.9 µm; Thermo
Fisher Scientific, MA, USA) as used previously.35 Mobile phase
A: 60% acetonitrile/water (10 mM ammonium formate, 0.1%
formic acid); mobile phase B: 85.5% propan-2-ol/9.5% aceto-
nitrile/5% water (10 mM ammonium formate, 0.1% formic
acid). Gradient: t = 0.0, 20% B; t = 0.5, 20% B, t = 8.5, 100% B;
t = 9.5, 100% B; t = 11.5, 20% B; t = 14.0, 20% B. All changes
were linear (curve = 5) and the flow rate was 0.40 mL min−1.
Column temperature was 55 °C and injection volume was 2 μL.
Data were acquired in positive and negative ionisation mode
separately (150–2000 m/z) with a resolution 70 000. Ion source
parameters: sheath gas = 50 arbitrary units, aux. gas = 13 arbi-
trary units, sweep gas = 3 arbitrary units, spray voltage = 3.5 kV
(positive ion)/2.5 kV (negative ion), capillary temp. = 263 °C,
aux. gas heater temp. = 425 °C. Data dependent MS2 in
‘Discovery mode’ was applied to three QCs over three mass
ranges (200–400 m/z; 400–700 m/z; 700–1500 m/z) using the fol-
lowing settings: resolution = 17 500; isolation width = 3.0 m/z;
stepped normalised collision energies = 20, 50, 80%.
Thermo ExactiveTune (2.8 SP1, build 2806) software con-
trolled the instrument. All data were acquired in profile mode.
Quality control (QC) samples were analysed as the first ten
injections and then every tenth injection with two at the end
of the analytical batch. An extract blank sample was analysed
as the 6th injection. Extract blank samples from all extraction
methods were analysed at the end of the batch.
2.8. Raw data processing and metabolite annotation
Fig. S1† visualises the data processing pipeline. Vendor format
raw data files (.RAW) were converted to the mzML file format
using ProteoWizard software (settings: peakPicking at vendor
msLevel = 1; selected options = 64-bit, write index, use zlib
compression, TPP compatible).36 Deconvolution was per-
formed by XCMS software37 (version 1.46.0 running in the
Galaxy environment38) applying min peak width (urine
reversed phase = 3; HILIC = 4; lipids = 6); max. peak width
(30); ppm (urine reversed phase = 11; HILIC = 12; lipids = 14);
mzdiff (0.001); bw (urine reversed phase = 0.5; HILIC and
lipids = 0.25); mzwid (0.01); minfrac (0.2). A data matrix of
peak areas for metabolite features (m/z-retention time pairs)
vs. samples were constructed. Putative metabolite annotation
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was performed applying PUTMEDID-LCMS (5 ppm mass error
for metabolite matching; 2 s retention time range for feature
grouping).39 Multiple annotations (e.g. isomeric compounds)
could be observed for a single detected metabolite feature.
Throughout this article, the term putatively annotated metab-
olite refers to either single metabolites or groups of molecules
with the same retention time and the same accurate m/z.
To generate more robust compound annotations, QC
sample UHPLC-MS/MS data were matched to MS/MS databases
using either LipidSearch software (lipid annotation; version
4.2.18, Thermo Fisher Scientific) or Compound Discoverer 3
software (polar compound and some lipid annotations;
version 3, Thermo Fisher Scientific) (Fig. S1†). Lipid features
within the UHPLC-MS/MS data were searched against the
entire in silico HCD MS/MS database (5 ppm mass error). Only
annotations graded A-C were used for annotation purposes
(Grade A – all fatty acyl chains and class were completely
identified; Grade B – some fatty acyl chains and the class were
identified; Grade C – either the lipid class or some fatty acyls
were identified). MS/MS annotations using Compound
Discoverer were graded by HighChem HighRes algorithm
within the Compound Discoverer software (annotations with a
score >60 were retained for identification purposes).
LipidSearch and Compound Discoverer annotations were
aligned to the XCMS outputs using the R programming
language (https://www.R-project.org), using 5 ppm mass error
and 20 s retention time tolerance window.
2.9. Data filtering using QC samples to generate the putative
metabolite and lipid data shown throughout the study
An overview of data filtering is shown in Fig. S1.† The first 8
QC samples and QC samples with a total peak area (of all
metabolites) exceeding ±25% of the median QC total peak area
were removed from the data matrix. Features were retained in
the data matrix if they were: present in >70% of QC samples;
had a peak area relative standard deviation (RSD) < 30% across
QC samples; and had an extract blank/mean QC area ratio of
<5%. This filtering retains highly robust and reproducible fea-
tures across 8–14 QC injections over a >24 h period, an impor-
tant step as feature stability and reproducibility over a long
time period is essential for metabolic phenotyping studies.
Only features with putative metabolite annotations (a matched
metabolic formula from PUTMEDID-LCMS) were retained. For
each putatively annotated metabolite, only the metabolite ion
form with the largest peak area were retained (using mean
peak area of all samples across all preparation conditions).
2.10. Statistics
For each preparation method, un-normalised peak area relative
standard deviation (RSD) values were calculated for peaks
present in all three sample preparation replicates or
UHPLC-MS injection triplicates. Venn diagrams40 were gener-
ated using the R programming language (https://www.R-
project.org). For principal components analysis (PCA) the
above filtered data matrices were processed to retain peaks
present across >80% of all samples. Then matrices were nor-
malised (probabilistic quotient normalisation41), missing data
values were imputed (k nearest neighbour, kNN) and a general-
ised log transformation was applied.42 PCA was conducted
using PLS Toolbox in Matlab. The other processing steps




3. Results and discussion
3.1. Optimised urine sample preparation for the C18 aqueous
reversed-phase UHPLC-MS assay
Four of the five methods (50 : 50 ACN : H2O, 50 : 50
MeOH : H2O, 100% MeOH, 50 : 50 ACN :MeOH) had high
reproducibility for positive and negative ion modes: median
sample preparation peak area relative standard deviations
(RSDs) were 6.7–7.7% (Fig. 1, no solvent incubation) and
median UHPLC-MS injection peak area RSDs were 6.5–7.3%
(Fig. S2,† no solvent incubation). Preparation replicates for
these methods were tightly clustered on the principal com-
ponents analysis (PCA) scores plot (Fig. S3†). 100% ACN had
poor sample preparation and injection reproducibility (Fig. 1
and S2†) and decreased putative metabolite counts relative to
other methods. This effect was less apparent in the positive
ion data compared to the negative ion data (Fig. 1). In the posi-
tive ion data only 100% ACN preparation with 60 min incu-
bation at 4 °C had increased variability and low reproducible
putative metabolite counts, which was attributable to the
single outlier visible on the PCA scores plot (Fig. S3;† post
outlier removal median RSD was 5.2% and the count of puta-
tive metabolites with an RSD < 30% was 2269). In this
instance, the data suggests that it was either a single miss
injection or that this method has sporadic poor reproducibil-
ity. In negative ion, the poor reproducibility was also apparent
in the UHPLC-MS injection data (Fig. S2†). Observing the
UHPLC-MS injection data, situations where the reproducibility
was poor was associated with large spectral variances of peaks
with <1 minute retention time (Fig. S4†). Further investigation
revealed that features putatively annotated as citrate and isoci-
trate were present in this early retention time window and
showed high peak area variability in the negative ion data
(Fig. S4†). Given that these compounds would predominantly
ionise negatively, this could indicate why negative ion mode
was generally lower reproducibility than positive ion mode. In
support of this observation, inspection of MS/MS annotated
peaks extracted by 100% ACN showed that several other acidic
compounds have poor reproducibility in the negative ion data
(Table S1†). In 100% ACN the peaks with a retention time of
<1 minute had higher peak areas than in the other preparation
methods (Fig. S4 and S5†), accounting for the general higher
total peak area in 100% ACN compared to other methods. We
conclude that 100% ACN is not recommended for this method
based on poor reproducibility. Potential reasons for poor
reproducibility include immiscibility either (i) within the final
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prepared sample or (ii) when the sample [high ACN content]
mixes with the initial mobile phase conditions [high water
content], which results in sporadic injection variance. All other
methods did not experience this issue (Fig. 1 and Fig. S2†).
The four reproducible methods (i.e. excluding 100% ACN)
had similar numbers of detected putative metabolites (Fig. 1;
74–78% putative metabolites were detected by all four
methods, Fig. S6†). The UHPLC-MS chromatograms and many
classes of metabolite showed similar detection responses
across these methods (Fig. 2, Fig. S5 and Table S1†). These
findings demonstrate much overlap between the four
methods, however, the PCA scores plot highlights small differ-
ences in metabolite responses or detection between methods
(Fig. S3†). Varying urine–solvent incubation time or tempera-
ture had minimal effect on reproducibility, putative metabolite
count, metabolite response, or metabolic profile (Fig. 1, Fig. S3
and Table S2†) suggesting incubations have minimal effect on
sample extraction (extraction being the removal of any residual
protein present in urine from renal damage or bacterial infec-
tion). The biofluid–solvent incubation data can also be used to
assess the stability of the sample post-extraction (given that
protein content of normal urine samples is expected to be
close to zero). For all urine sample preparation methods ana-
lysed by the C18 aqueous reversed-phase UHPLC-MS assay,
extremely few features showed significant change after incu-
bation with solvent (for all methods, <0.5% features were stat-
istically altered with incubation, FDR < 5%; Table S3†). This
demonstrated the high stability of all sample preparation
methods post-preparation. We conclude that any tested
method except 100% ACN is suitable for C18 aqueous reversed
phase UHPLC-MS urine metabolomics and urine–solvent incu-
bation is not required. We recommend 50 : 50 MeOH : H2O as
it avoids acetonitrile use which may mix poorly with water at
the beginning of our C18 aqueous reversed phase UHPLC-MS
assay.
3.2. Optimised urine sample preparation for the HILIC
UHPLC-MS assay
All methods had median sample preparation and UHPLC-MS
injection peak area RSDs of <10% (except 50 : 50 ACN : H2O
with no solvent incubation and 50 : 50 MeOH : ACN with
60 min −20 °C incubation; Fig. 1 and S2†), demonstrating
Fig. 1 Sample preparation replicate data for putatively annotated metabolites from all urine sample preparation methods. Data were filtered using
QC samples and then putatively annotated (Experimental section). Relative standard deviations (RSD; shown as interquartile ranges and error bars as
the 95th percentile) are calculated on peak areas where the putative metabolite is present in all three sample preparation replicates. Putatively anno-
tated metabolite counts are those in three sample preparation replicates with a peak area RSD < 30%.
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little sample preparation or injection technical variance. PCA
scores plots further demonstrate high sample preparation
reproducibility (Fig. S7†). The low sample preparation and
UHPLC-MS injection reproducibility of 50 : 50 ACN : H2O (no
incubation, negative ion; Fig. 1 and S2†) suggested poor injec-
tion reproducibility as seen for 100% ACN method with the
urine C18 aqueous reversed phase assay (section 3.1). Few MS/
MS annotated compounds were observed in the negative ion
HILIC assay, however MS/MS-annotated cholic acid had poor
reproducibility here (Table S1†). Reproducibility was improved
by urine–solvent incubation, however given that the reproduci-
bility issues may be caused by immiscibility of the sample with
initial mobile phase conditions (potentially an issue with high
water mixing with high ACN at the beginning of an analysis as
suggested for the urine C18 aqueous reversed phase assay,
section 3.1) this method is not recommended. Poor reproduci-
bility of 50 : 50 MeOH : ACN (60 min incubation, −20 °C;
Fig. 1) was caused by low total peak area of one sample prepa-
ration replicate. This suggested a detrimental effect of incu-
bation; however, the metabolic profile was corrected by nor-
malisation as viewed on the PCA scores plot (Fig. S7†).
The four reproducible methods (100% ACN, 50 : 50
MeOH : H2O, 100% MeOH, 50 : 50 ACN :MeOH) had similar
putative metabolite counts in positive ion mode (Fig. 1): 100%
ACN (2505 putatively identified metabolites), 100% MeOH
(2468), 50 : 50 ACN :MeOH (2452) and 50 : 50 MeOH : H2O
(2339). In negative ion mode, 50 : 50 ACN :MeOH had the
highest putative metabolite count (2733) followed by 100%
ACN (2369), MeOH : H2O (2369) and MeOH (2173) (Fig. 1).
There was overlap between methods (62–67% [positive ion]
and 52–66% [negative ion] of putative metabolites were
detected by all four methods (Fig. S8†), however this was less
overlap than for the urine C18 aqueous reversed phase
UHPLC-MS assay (Fig. S6†). This is partly due to lower
UHPLC-MS injection reproducibility of the urine HILIC assay
compared to the urine C18 aqueous assay (Fig. S2†), which
negatively affects putative metabolite counts with an RSD
threshold. Consistent with this, 50 : 50 ACN :MeOH (HILIC
negative ion) had the lowest RSD and highest putative metab-
olite count (RSD < 30%), demonstrating the importance of
method reproducibility. UHPLC-MS chromatograms (Fig. S9†)
and metabolite responses of the four reproducible methods
were similar (Fig. 2). However, some differences between
methods were apparent on the PCA scores plot (Fig. S7†). This
was partly due to the acylcarnitine response (highest in 100%
MeOH and 50 : 50 ACN :MeOH, and lowest in 100% ACN;
Fig. 2), suggesting ACN is less effective for lipid recovery than
MeOH. The 50 : 50 ACN : H2O had lower putative metabolite
counts but higher total peak area than all other methods. This
appears to be due to 50 : 50 ACN : H2O providing the best
environment for very polar metabolites (in terms of solubility
and/or ionisation efficiency, Fig. 2 and Table S1†). However,
this method performs much poorer with less polar com-
pounds, which is highlighted by high detection responses of
very polar acylcarnitines but low detection responses of less
polar acylcarnitines (Fig. S10†), which could account for the
lower putative metabolite counts.
Varying the urine–solvent incubation time or temperature
had little effect on reproducibility, putative metabolite count,
metabolite response, or metabolic profile (Fig. 1, Fig. S7 and
Table S2†). For all urine sample preparation methods analysed
by the HILIC UHPLC-MS assay, extremely few features showed
significant change after incubation with solvent (for all
methods, <0.6% features were statistically altered with incu-
bation, FDR < 5%; Table S3†). This is consistent with the C18
aqueous reversed-phase UHPLC-MS data and demonstrates the
high stability of all sample preparation methods post-prepa-
ration. We conclude that, in terms of reproducibility and
Fig. 2 Selected MS/MS-annotated metabolites detected by HILIC and C18 aqueous reversed phase analysis of polar metabolite preparations of
plasma or urine. UHPLC-MS peak area for each annotated compound is shown as mean ± sd (n = 3 preparation replicates; no solvent incubation for
monophasic and 1 min partition time for biphasic methods). Metabolites were annotated from QC UHPLC-MS/MS data using Compound Discoverer
and Lipid Search software (m/z, retention times, MS/MS annotation grade, mean peak area and standard deviations for each compound shown here
plus additional compounds are shown in Table S1†). All annotated acylcarnitines were summed.
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detected putative metabolites, 50 : 50 ACN :MeOH with no
urine–solvent incubation is recommended for both positive
and negative ionisation HILIC analysis. Although 50 : 50
ACN : H2O appeared to provide a greater detection response for
the eight chosen metabolites (Fig. 2), the reproducibility of
replicate injections and the number of putative metabolites
detected was not analytically appropriate.
3.3. Optimised plasma sample preparation for the HILIC
UHPLC-MS assay
Considering monophasic preparation methods, median
sample preparation peak area RSDs (no incubation) were
8.2–9.4% and 7.3–8.0% for positive and negative ion, respect-
ively (Fig. 3) and median UHPLC-MS injection peak area RSDs
were 5.9–8.1% and 6.5–7.0% for positive and negative ion,
respectively (Fig. S11†). Along with the tight clustering of
sample preparation replicates on the PCA scores plot
(Fig. S12†), this demonstrates very little sample preparation
and injection technical variance. The monophasic method (no
solvent incubation) with the highest number of reproducible
putative metabolites was 50 : 50 ACN :MeOH for both positive
(1173) and negative (790) ion modes (Fig. 3), followed by 100%
ACN (positive 1111; negative 620) and 100% MeOH (positive
1032; negative 642). The UHPLC-MS chromatograms and
metabolites showed similar detection responses across the
monophasic methods (Fig. 2, Fig. S13 and Table S1†). There
was an apparent trend for amino acids and related compounds
(kynurenine, tryptophan, threonine) where the response was
highest in 100% MeOH, indicating that methanol is the best
for extraction of such compounds or can provide the greatest
ionisation efficiency (Fig. 2 and Table S1†). Multiple lipid
classes were extracted by the monophasic methods, with
50 : 50 MeOH : ACN and 100% MeOH methods having a higher
detection response than 100% ACN (for phosphatidylcholines,
phosphatidylethanolamines and sphingomyelines; Fig. 4).
Solvent incubation had minimal effect on sample preparation
reproducibility or the number of detected putative metabolites
(Fig. 3), however solvent incubation during the 50 : 50
ACN :MeOH method (60 min at 4 °C or −20 °C) induced a
shift on the PCA scores plot (Fig. S12†). Several phosphatidyl-
choline, phosphatidylinositol and sphingomyelin species had
higher responses after incubation (Table S2†), indicating
Fig. 3 Sample preparation replicate data for putatively annotated metabolites and lipids from all plasma sample preparation methods. This data was
filtered using QC samples and then putatively annotated (Methods section). Relative standard deviations (RSD; shown as interquartile ranges and
error bars as the 95th percentile) are calculated on peak intensities where the putative metabolite/lipid is present in all three sample preparation
replicates. Putatively annotated metabolite/lipid counts are those present in three sample preparation replicates with an area RSD < 30%.
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enhanced lipid extraction with incubation for this method.
The 100% ACN method also showed higher response of some
lipids after solvent incubation (Table S2†).
Considering biphasic preparation methods, median
sample preparation peak area RSDs (1 min partition time)
were 8.9–9.2% and 7.9–8.2% for positive and negative ion,
respectively (Fig. 3) and median UHPLC-MS injection peak
area RSDs were 6.2–8.7% and 6.5–7.1% for positive and nega-
tive ion, respectively (Fig. S11†). Along with the PCA scores
plot (Fig. S12†), this demonstrates low sample preparation
and injection technical variance similar to the monophasic
methods. The biphasic method (1 min partition time) with
the most detected putative metabolites was
MTBE : MeOH : H2O in positive (1136) and negative ion modes
(736), followed by DCM :MeOH : H2O (924 pos., 705 neg.) and
CHCl3 : MeOH : H2O (852 pos., 707 neg.). With the exception
of DCM :MeOH : H2O and CHCl3 : MeOH : H2O in positive ion
mode, these values were similar to the monophasic methods.
The lower detection response of DCM :MeOH : H2O and
CHCl3 : MeOH : H2O in positive ion mode was attributed to
decreased lipid detection response (Fig. 4; visible in the
UHPLC-MS chromatogram, ∼RT 4.2 min, Fig. S13A†), indicat-
ing these methods are the best for lipid removal from the
polar phase. This is noteworthy because phospholipid
removal from polar extracts can lower ionisation suppression
and ion competition during UHPLC-MS analysis.24 The high
polar metabolite yield of MTBE : MeOH : H2O relative to the
other biphasic methods is consistent with previous obser-
vations,13 and may be due to the lower polarity of MTBE rela-
tive to chloroform and dichloromethane causing a greater
number or concentration of polar compounds (and polar
lipids, Fig. 4) to partition into the aqueous phase.
Considering polar metabolites, there was a similar detection
response across the three biphasic methods (Fig. 2 and
Table S1†). Increasing CHCl3 : MeOH : H2O partition time
increased the polar metabolite and very polar lipid (e.g. acyl
carnitines) responses in the polar extract (Table S2†).
Increasing partition time for MTBE : MeOH : H2O and
DCM :MeOH : H2O methods, decreased the lipid detection
response in the polar extract (Table S2†). These small changes
indicate that the longer partition step allows phase-partition
to get closer to equilibrium.
We conclude that monophasic 50 : 50 ACN :MeOH is the
optimal method in terms of reproducibility and number of
detected putative metabolites. As a monophasic method it is a
shorter, quicker and simpler procedure than biphasic
methods. Plasma–solvent incubation is not recommended as
(i) there is no reproducibility or yield improvement, and (ii) it
can enhance lipid extraction, which is not necessarily desirable
in polar sample preparations. CHCl3 : MeOH : H2O is the rec-
ommended biphasic method as it provides the best lipid
removal from the polar extract, while also providing good
reproducibility and detection sensitivity. A 20 min partition is
recommended as it allows phase-partitioning to reach
equilibrium.
3.4. Optimised plasma sample preparation for the C18
reversed phase lipids UHPLC-MS assay
Monophasic sample preparation methods containing some
isopropanol (25 : 75 ACN : IPA, 50 : 50 ACN : IPA, 75 : 25
ACN : IPA, 100% IPA) were highly reproducible (Fig. 3). For
these methods (with no solvent incubation) median sample
preparation peak area RSDs were 4.7–6.9% and 4.5–6.6% for
positive and negative ion, respectively (Fig. 3), and median
UHPLC-MS injection peak area RSDs were 3.9–4.3% and
4.1–4.7% for positive and negative ion, respectively (Fig. S11†),
demonstrating minimal technical variance arising from
sample preparation and sample analysis. PCA scores plots
(Fig. S14†) provide further evidence of high reproducibility and
showed that the higher the IPA content, the higher the
method reproducibility (Fig. S14†). 100% ACN had higher
median sample preparation peak area RSDs (no solvent incu-
bation: positive ion 10.3%; negative ion 12.4%) than IPA-based
methods, indicating greater sample preparation technical var-
iance. Lipid classes that had poor reproducibility in the 100%
ACN included ceramides, some phosphatidylcholines and
some triglycerides (Table S1†). Ceramides and triglycerides are
very non-polar lipids, suggesting 100% ACN is not suitable for
the extraction of very non-polar compounds.
Fig. 4 MS/MS-annotated lipids detected in the HILIC UHPLC-MS ana-
lysis of polar metabolite extractions of plasma. UHPLC-MS positive ion
total peak area for each annotated lipid class is shown as mean ± sd (n =
3 preparation replicates; no solvent incubation for monophasic and
1 min partition time for biphasic methods). Lipids were annotated from
QC UHPLC-MS/MS data using Lipid Search software (m/z, retention
times, MS/MS annotation grade, mean peak area and standard deviations
for each lipid species is shown in Table S1†).
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Considering putative metabolite and lipid detection, 25 : 75
ACN : IPA and 100% IPA had the highest for both positive
(1680–1682 putative metabolites/lipids) and negative (839–845)
ion modes (Fig. 3). The lipid detection response and number
of detected putative metabolites/lipids increased with increas-
ing IPA content (Fig. 3, Fig. 5 and Table S1;† also visible in the
base peak chromatograms, Fig. S15†), consistent with previous
findings.12 Incubation with extraction solvent had little effect
on reproducibility or numbers of detected putative metabolites
or lipids, except for 100% ACN where solvent incubation
(60 min at 4 °C or 60 min at −20 °C) showed a small increase
in reproducibility and numbers of detected putative metab-
olites/lipids (Fig. 3).
Biphasic methods (1 min partition time) had higher
sample preparation variance than monophasic methods con-
taining IPA: median sample preparation peak area RSDs were
8.5–21.5% and 7.4–24.6% (positive and negative ion, respect-
ively; Fig. 3); and median UHPLC-MS injection peak area RSDs
were 4.0–4.1% and 3.9–4.3% (positive and negative ion,
respectively; Fig. S11†). The increased variance was likely
caused by additional steps in biphasic extraction procedures
(pipetting, drying and reconstitution) compared to monopha-
sic procedures. Biphasic methods had a lower lipid detection
response and detected fewer putatively annotated metabolites
or lipids than monophasic methods (Fig. 3, 5 and Table S1†),
consistent with previous observations.12,16 This is due to lower
recovery of polar lipids which partition into both the polar and
non-polar phases (Fig. 4 and 5) and potential loss of com-
pounds during drying and reconstitution stages, steps that are
not present in monophasic methods. Increasing
CHCl3 : MeOH : H2O biphasic partition time (20 min) improved
method reproducibility and detection of putatively annotated
metabolites/lipids (as observed with tissues previously14), but
increasing partition time had no improvement for the other
biphasic methods (Fig. 3).
We conclude that monophasic 100% IPA is the preferred
method because (i) it is the most reproducible method, (ii) it
has the highest yield for all lipid classes, including both polar
(e.g. acyl carnitines) and non-polar (e.g. triglycerides), and (iii)
it is a simple and rapid method (Fig. 5). Plasma–solvent incu-
bation does not improve yield or reproducibility so is not rec-
ommended. Where the sample volume is insufficient for sep-
arate polar and non-polar preparations, we recommend
CHCl3 : MeOH : H2O biphasic (20 min partition) as it provides
the highest lipid response for a biphasic method with an
acceptable level of reproducibility (Fig. 3 and 5).
Considering the results from sections 3.3 and 3.4, biphasic
methods had higher final extraction plasma : solvent ratios
compared to monophasic methods (monophasic 1 : 3, biphasic
methods with CHCl3 or DCM 1 : 17.6, biphasic methods with
MTBE 1 : 21.4). However, following drying and reconstitution
of biphasic samples, all injected samples from all methods
had an equivalent plasma dilution. The higher extraction
solvent volumes would be expected to improve extraction
efficiency (more solvent space for compounds to partition into)
and reproducibility (easier to pipette large volumes reproduci-
Fig. 5 MS/MS-annotated lipids detected in the C18 UHPLC-MS analysis
of lipid extractions of plasma. UHPLC-MS positive ion total peak area for
each annotated lipid class is shown as mean ± sd (n = 3 preparation
replicates; no solvent incubation for monophasic and 1 min partition
time for biphasic methods). Lipids were annotated from QC UHPLC-MS/
MS data using Lipid Search software (m/z, retention times, MS/MS anno-
tation grade, mean peak area and standard deviations for each lipid
species is shown in Table S1†).
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bly); however even with these proposed benefits, biphasic
methods generally performed worse than monophasic
methods in terms of yield and reproducibility.
4. Conclusions
We compared multiple monophasic (urine and plasma) and
biphasic (plasma) sample preparation methods for UHPLC-MS
metabolic and lipid phenotyping, assessing methods in terms
of reproducibility and yield. Yield was assessed by the
numbers of detected putatively annotated metabolites (based
on accurate mass) and the responses of MS/MS-annotated
metabolites and lipids. Biphasic extracts were dried and recon-
stituted before UHPLC-MS analysis whereas monophasic prep-
arations were directly injected on to the UHPLC column. This
was done for two reasons: (i) biphasic lipid extracts were not
suitable for direct injection onto UHPLC columns and (ii) it
allowed us to accurately match plasma dilutions during mono-
phasic and biphasic preparations. The recommended sample
preparation methods for urine are monophasic 50 : 50
MeOH : H2O for C18 aqueous reversed phase assay and mono-
phasic 50 : 50 ACN :MeOH for the HILIC assay (in both cases
1 : 3 urine/solvent; no plasma–solvent incubation). For each
UHPLC-MS assay, these methods detected the highest number
of putative metabolites, demonstrated high sample prepa-
ration reproducibility and were appropriate solvents for direct
injection onto the UHPLC column. The recommended method
for plasma polar HILIC UHPLC-MS metabolomics is mono-
phasic 50 : 50 ACN :MeOH (1 : 3 plasma/solvent; no plasma–
solvent incubation) as this detected the highest number of
putative metabolites with high reproducibility. The biphasic
CHCl3 : MeOH : H2O method (20 min partition) is rec-
ommended for plasma HILIC UHPLC-MS analysis where lipid
removal from the polar extract was required. 100% IPA (1 : 3
plasma/solvent; no plasma–solvent incubation) is rec-
ommended for plasma C18 lipidomics due to high reproduci-
bility and the highest detection responses for all measured
lipid classes. Biofluid–solvent incubation during monophasic
preparation provides no improvement in yield or reproducibil-
ity and is not required. The monophasic methods we rec-
ommend are simple, quick and high-throughput procedures
ideal for large metabolic phenotyping studies. A limitation of
the study is that isotopically labelled internal standard com-
pounds were not used. Isotopically-labelled internal standard
(s) can be used to check any change in reproducibility within
each analysed sample for the exact non-isotopically labelled
version of the specific internal standard(s) used (given that
factors affecting reproducibility [e.g. matrix effects] are specific
to compound retention time and will thus will be different for
different compounds). Here, we assessed the reproducibility of
multiple chemically diverse endogenous compounds (putative
and MS/MS annotated) in three different ways: (i) repeat injec-
tions of a homogenous quality control (QC) sample at regular
intervals throughout the analytical run to monitor analytical
detection performance, (ii) for each sample preparation
method we measured sample preparation replicates to
measure the combined sample preparation and UHPLC-MS
injection variance, and (iii) for each sample preparation
method we measured UHPLC-MS injection reproducibility to
measure the variance directly attributable to UHPLC-MS per-
formance. Isotopically labelled internal standards are an
easier and quicker way to define instrument variance versus
sample preparation variance compared to our approach used
here (analysis of separate sample preparation and UHPLC-MS
injection replicates), therefore we would advise the use of iso-
topically labelled internal standards for this purpose in future
biological studies.
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